Genprex enters new sponsored research agreement with University of Pittsburgh for GPX-002 diabetes gene therapy

Genprex, Inc.

New SRA with Pitt for preclinical studies of GPX-002 in T1D and T2D animal models.
Preclinical T1D data showed statistically significant decreases in insulin requirements and increases in c-peptide levels.
GPX-002 uses adeno-associated virus vector with Pdx1 and MafA genes delivered via pancreatic duct.
In T1D, GPX-002 aims to transform alpha cells into functional beta-like cells to evade immune system.
In T2D, GPX-002 is believed to rejuvenate exhausted beta cells.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.